These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 27430985

  • 21. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N.
    Grzmil M, Qin Y, Schleuniger C, Frank S, Imobersteg S, Blanc A, Spillmann M, Berger P, Schibli R, Behe M.
    Theranostics; 2020; 10(24):10861-10873. PubMed ID: 33042258
    [Abstract] [Full Text] [Related]

  • 22. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
    Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E.
    Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
    [Abstract] [Full Text] [Related]

  • 23. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides.
    Breeman WA, Fröberg AC, de Blois E, van Gameren A, Melis M, de Jong M, Maina T, Nock BA, Erion JL, Mäcke HR, Krenning EP.
    Nucl Med Biol; 2008 Nov; 35(8):839-49. PubMed ID: 19026945
    [Abstract] [Full Text] [Related]

  • 24. Conformational behavior of cyclic CCK-related peptides determined by 400-MHz 1H-NMR: relationships with affinity and selectivity for brain receptors.
    Roy P, Charpentier B, Durieux C, Dor A, Roques BP.
    Biopolymers; 1989 Jan; 28(1):69-79. PubMed ID: 2720122
    [Abstract] [Full Text] [Related]

  • 25. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
    Behr TM, Béhé M, Angerstein C, Gratz S, Mach R, Hagemann L, Jenner N, Stiehler M, Frank-Raue K, Raue F, Becker W.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
    [Abstract] [Full Text] [Related]

  • 26. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors.
    Laverman P, Béhé M, Oyen WJ, Willems PH, Corstens FH, Behr TM, Boerman OC.
    Bioconjug Chem; 2004 Oct; 15(3):561-8. PubMed ID: 15149184
    [Abstract] [Full Text] [Related]

  • 27. Cyclic cholecystokinin analogues with high selectivity for central receptors.
    Charpentier B, Pelaprat D, Durieux C, Dor A, Reibaud M, Blanchard JC, Roques BP.
    Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1968-72. PubMed ID: 3162318
    [Abstract] [Full Text] [Related]

  • 28. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M, Behr TM.
    Biopolymers; 2002 Mar; 66(6):399-418. PubMed ID: 12658727
    [Abstract] [Full Text] [Related]

  • 29. Potential therapeutic radiotracers: preparation, biodistribution and metabolic characteristics of 177Lu-labeled cyclic RGDfK dimer.
    Shi J, Liu Z, Jia B, Yu Z, Zhao H, Wang F.
    Amino Acids; 2010 Jun; 39(1):111-20. PubMed ID: 19941017
    [Abstract] [Full Text] [Related]

  • 30. Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs.
    Holzleitner N, Fischer S, Maniyankerikalam I, Beck R, Lapa C, Wester HJ, Günther T.
    EJNMMI Res; 2024 Mar 02; 14(1):23. PubMed ID: 38429609
    [Abstract] [Full Text] [Related]

  • 31. [68Ga]Ga/[177Lu]Lu-BL01, a Novel Theranostic Pair for Targeting C-X-C Chemokine Receptor 4.
    Lau J, Kwon D, Rousseau E, Zhang Z, Zeisler J, Uribe CF, Kuo HT, Zhang C, Lin KS, Bénard F.
    Mol Pharm; 2019 Nov 04; 16(11):4688-4695. PubMed ID: 31545614
    [Abstract] [Full Text] [Related]

  • 32. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW, Nikiforovich GV, Haskell-Luevano C, Fang SN, Zalewska T, Stropova D, Yamamura HI, Hruby VJ.
    J Med Chem; 1996 Sep 27; 39(20):4120-4. PubMed ID: 8831778
    [Abstract] [Full Text] [Related]

  • 33. 177Lu Labeled Cyclic Minigastrin Analogues with Therapeutic Activity in CCK2R Expressing Tumors: Preclinical Evaluation of a Kit Formulation.
    Rangger C, Klingler M, Balogh L, Pöstényi Z, Polyak A, Pawlak D, Mikołajczak R, von Guggenberg E.
    Mol Pharm; 2017 Sep 05; 14(9):3045-3058. PubMed ID: 28728415
    [Abstract] [Full Text] [Related]

  • 34. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
    Klingler M, Summer D, Rangger C, Haubner R, Foster J, Sosabowski J, Decristoforo C, Virgolini I, von Guggenberg E.
    J Nucl Med; 2019 Jul 05; 60(7):1010-1016. PubMed ID: 30530828
    [Abstract] [Full Text] [Related]

  • 35. Synthesis and biological evaluation of a novel (177)Lu-DOTA-[Gly(3)-cyclized(Dap(4), (d)-Phe(7), Asp(10))-Arg(11)]α-MSH(3-13) analogue for melanocortin-1 receptor-positive tumor targeting.
    Lim JC, Hong YD, Kim JJ, Choi SM, Baek HS, Choi SJ.
    Cancer Biother Radiopharm; 2012 Oct 05; 27(8):464-72. PubMed ID: 22831553
    [Abstract] [Full Text] [Related]

  • 36.
    Cheng KT.
    ; 2004 Oct 05. PubMed ID: 20641278
    [Abstract] [Full Text] [Related]

  • 37. Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals.
    Müller C, Farkas R, Borgna F, Schmid RM, Benešová M, Schibli R.
    Bioconjug Chem; 2017 Sep 20; 28(9):2372-2383. PubMed ID: 28898054
    [Abstract] [Full Text] [Related]

  • 38.
    Cheng KT.
    ; 2004 Sep 20. PubMed ID: 20641328
    [Abstract] [Full Text] [Related]

  • 39. Preclinical evaluation of new GnRH-I receptor radionuclide therapy with 177 Lu-peptide tracer.
    Zoghi M, Attar Nosrati S, Rogni F, Shirvani G, Johari Daha F.
    J Labelled Comp Radiopharm; 2019 Jun 15; 62(7):310-320. PubMed ID: 31033025
    [Abstract] [Full Text] [Related]

  • 40. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Koumarianou E, Mikołajczak R, Pawlak D, Zikos X, Bouziotis P, Garnuszek P, Karczmarczyk U, Maurin M, Archimandritis SC.
    Nucl Med Biol; 2009 Aug 15; 36(6):591-603. PubMed ID: 19647165
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.